Transcatheter Arterial Embolization in the Treatment of Maxillofacial Fractures with Life-Threatening Hemorrhage

Shokei Matsumoto, Taku Akashi, Kei Hayashida, Kazuhiko Sekine, Tomohiko Orita, Tomohiro Funabiki, Mitsuhide Kitano

Research output: Contribution to journalArticle

Abstract

Introduction Transcatheter arterial embolization (TAE) has gained importance in the management of maxillofacial fractures with life-threating hemorrhage (MFH). However, clinical evidence supporting the use of TAE has not been clearly established in the literature. Therefore, we evaluated the effectiveness of TAE for MFH, based on data obtained from the Japan Trauma Data Bank. Methods Patients were identified from Japan Trauma Data Bank entries for the years 2004 to 2014. Inclusion criteria for MFH were defined using the Abbreviated Injury Scale code (Maxilla fracture, LeFort III; blood loss. > 20%). On the basis of the treatment strategy, patients were categorized into either the TAE group or the non-TAE group. A comparative analysis of the demographics, injury characteristics, and outcomes was performed. Results From among 198,744 documented cases of trauma, a total 118 patients were eligible for the study; 26 of these patients (22.0%) underwent TAE. The Glasgow Coma Scale score was significantly lower in the TAE group than in the non-TAE group (P = 0.019); the other variables did not significantly differ between the groups. Overall, the in-hospital mortality rate was 39.8%, and the median hospital length of stay was 21.0 days (0.0-53.5 days). The in-hospital mortality was significantly lower in the TAE group than in the non-TAE group (23.1% vs 44.6%; odds ratio [OR], 0.37; 95% confidence interval [CI], 0.14-1.02; p = 0.048). However, patients in the TAE group had a longer median hospital length of stay (39.5 [7.3-53.5] vs 14.0 [0.0-55.3] days, p = 0.072). In the logistic regression model, the use of TAE was extracted as the independent predictor for better outcomes after adjusting for potential confounders (OR, 0.32; 95% CI, 0.66-0.88; P = 0.032). Hypotension, a high Injury Severity Score, aged 60 years or older, and a low Glasgow Coma Scale score were also independently associated with mortality, with an OR of 5.48, 3.99, 3.30, and 2.89, respectively. Conclusions Cases of MFH are rare, but they are associated with a high mortality. Transcatheter arterial embolization use appears to lead to successful outcomes in such cases. Further studies are required to confirm the efficacy of TAE and evaluate its indications and complications.

Original languageEnglish
Pages (from-to)664-668
Number of pages5
JournalAnnals of Plastic Surgery
Volume80
Issue number6
DOIs
Publication statusPublished - 2018 Jun 1
Externally publishedYes

Fingerprint

Hemorrhage
Length of Stay
Glasgow Coma Scale
Odds Ratio
Wounds and Injuries
Hospital Mortality
Mortality
Japan
Logistic Models
Abbreviated Injury Scale
Databases
Confidence Intervals
Therapeutics
Injury Severity Score
Maxilla
Hypotension
Demography

Keywords

  • Japan Trauma Data Bank
  • life-threatening hemorrhage
  • maxillofacial fracture
  • transcatheter arterial embolization

ASJC Scopus subject areas

  • Surgery

Cite this

Transcatheter Arterial Embolization in the Treatment of Maxillofacial Fractures with Life-Threatening Hemorrhage. / Matsumoto, Shokei; Akashi, Taku; Hayashida, Kei; Sekine, Kazuhiko; Orita, Tomohiko; Funabiki, Tomohiro; Kitano, Mitsuhide.

In: Annals of Plastic Surgery, Vol. 80, No. 6, 01.06.2018, p. 664-668.

Research output: Contribution to journalArticle

Matsumoto, S, Akashi, T, Hayashida, K, Sekine, K, Orita, T, Funabiki, T & Kitano, M 2018, 'Transcatheter Arterial Embolization in the Treatment of Maxillofacial Fractures with Life-Threatening Hemorrhage', Annals of Plastic Surgery, vol. 80, no. 6, pp. 664-668. https://doi.org/10.1097/SAP.0000000000001405
Matsumoto, Shokei ; Akashi, Taku ; Hayashida, Kei ; Sekine, Kazuhiko ; Orita, Tomohiko ; Funabiki, Tomohiro ; Kitano, Mitsuhide. / Transcatheter Arterial Embolization in the Treatment of Maxillofacial Fractures with Life-Threatening Hemorrhage. In: Annals of Plastic Surgery. 2018 ; Vol. 80, No. 6. pp. 664-668.
@article{efd714a8357c45519a1dcdc5883979b0,
title = "Transcatheter Arterial Embolization in the Treatment of Maxillofacial Fractures with Life-Threatening Hemorrhage",
abstract = "Introduction Transcatheter arterial embolization (TAE) has gained importance in the management of maxillofacial fractures with life-threating hemorrhage (MFH). However, clinical evidence supporting the use of TAE has not been clearly established in the literature. Therefore, we evaluated the effectiveness of TAE for MFH, based on data obtained from the Japan Trauma Data Bank. Methods Patients were identified from Japan Trauma Data Bank entries for the years 2004 to 2014. Inclusion criteria for MFH were defined using the Abbreviated Injury Scale code (Maxilla fracture, LeFort III; blood loss. > 20{\%}). On the basis of the treatment strategy, patients were categorized into either the TAE group or the non-TAE group. A comparative analysis of the demographics, injury characteristics, and outcomes was performed. Results From among 198,744 documented cases of trauma, a total 118 patients were eligible for the study; 26 of these patients (22.0{\%}) underwent TAE. The Glasgow Coma Scale score was significantly lower in the TAE group than in the non-TAE group (P = 0.019); the other variables did not significantly differ between the groups. Overall, the in-hospital mortality rate was 39.8{\%}, and the median hospital length of stay was 21.0 days (0.0-53.5 days). The in-hospital mortality was significantly lower in the TAE group than in the non-TAE group (23.1{\%} vs 44.6{\%}; odds ratio [OR], 0.37; 95{\%} confidence interval [CI], 0.14-1.02; p = 0.048). However, patients in the TAE group had a longer median hospital length of stay (39.5 [7.3-53.5] vs 14.0 [0.0-55.3] days, p = 0.072). In the logistic regression model, the use of TAE was extracted as the independent predictor for better outcomes after adjusting for potential confounders (OR, 0.32; 95{\%} CI, 0.66-0.88; P = 0.032). Hypotension, a high Injury Severity Score, aged 60 years or older, and a low Glasgow Coma Scale score were also independently associated with mortality, with an OR of 5.48, 3.99, 3.30, and 2.89, respectively. Conclusions Cases of MFH are rare, but they are associated with a high mortality. Transcatheter arterial embolization use appears to lead to successful outcomes in such cases. Further studies are required to confirm the efficacy of TAE and evaluate its indications and complications.",
keywords = "Japan Trauma Data Bank, life-threatening hemorrhage, maxillofacial fracture, transcatheter arterial embolization",
author = "Shokei Matsumoto and Taku Akashi and Kei Hayashida and Kazuhiko Sekine and Tomohiko Orita and Tomohiro Funabiki and Mitsuhide Kitano",
year = "2018",
month = "6",
day = "1",
doi = "10.1097/SAP.0000000000001405",
language = "English",
volume = "80",
pages = "664--668",
journal = "Annals of Plastic Surgery",
issn = "0148-7043",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Transcatheter Arterial Embolization in the Treatment of Maxillofacial Fractures with Life-Threatening Hemorrhage

AU - Matsumoto, Shokei

AU - Akashi, Taku

AU - Hayashida, Kei

AU - Sekine, Kazuhiko

AU - Orita, Tomohiko

AU - Funabiki, Tomohiro

AU - Kitano, Mitsuhide

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Introduction Transcatheter arterial embolization (TAE) has gained importance in the management of maxillofacial fractures with life-threating hemorrhage (MFH). However, clinical evidence supporting the use of TAE has not been clearly established in the literature. Therefore, we evaluated the effectiveness of TAE for MFH, based on data obtained from the Japan Trauma Data Bank. Methods Patients were identified from Japan Trauma Data Bank entries for the years 2004 to 2014. Inclusion criteria for MFH were defined using the Abbreviated Injury Scale code (Maxilla fracture, LeFort III; blood loss. > 20%). On the basis of the treatment strategy, patients were categorized into either the TAE group or the non-TAE group. A comparative analysis of the demographics, injury characteristics, and outcomes was performed. Results From among 198,744 documented cases of trauma, a total 118 patients were eligible for the study; 26 of these patients (22.0%) underwent TAE. The Glasgow Coma Scale score was significantly lower in the TAE group than in the non-TAE group (P = 0.019); the other variables did not significantly differ between the groups. Overall, the in-hospital mortality rate was 39.8%, and the median hospital length of stay was 21.0 days (0.0-53.5 days). The in-hospital mortality was significantly lower in the TAE group than in the non-TAE group (23.1% vs 44.6%; odds ratio [OR], 0.37; 95% confidence interval [CI], 0.14-1.02; p = 0.048). However, patients in the TAE group had a longer median hospital length of stay (39.5 [7.3-53.5] vs 14.0 [0.0-55.3] days, p = 0.072). In the logistic regression model, the use of TAE was extracted as the independent predictor for better outcomes after adjusting for potential confounders (OR, 0.32; 95% CI, 0.66-0.88; P = 0.032). Hypotension, a high Injury Severity Score, aged 60 years or older, and a low Glasgow Coma Scale score were also independently associated with mortality, with an OR of 5.48, 3.99, 3.30, and 2.89, respectively. Conclusions Cases of MFH are rare, but they are associated with a high mortality. Transcatheter arterial embolization use appears to lead to successful outcomes in such cases. Further studies are required to confirm the efficacy of TAE and evaluate its indications and complications.

AB - Introduction Transcatheter arterial embolization (TAE) has gained importance in the management of maxillofacial fractures with life-threating hemorrhage (MFH). However, clinical evidence supporting the use of TAE has not been clearly established in the literature. Therefore, we evaluated the effectiveness of TAE for MFH, based on data obtained from the Japan Trauma Data Bank. Methods Patients were identified from Japan Trauma Data Bank entries for the years 2004 to 2014. Inclusion criteria for MFH were defined using the Abbreviated Injury Scale code (Maxilla fracture, LeFort III; blood loss. > 20%). On the basis of the treatment strategy, patients were categorized into either the TAE group or the non-TAE group. A comparative analysis of the demographics, injury characteristics, and outcomes was performed. Results From among 198,744 documented cases of trauma, a total 118 patients were eligible for the study; 26 of these patients (22.0%) underwent TAE. The Glasgow Coma Scale score was significantly lower in the TAE group than in the non-TAE group (P = 0.019); the other variables did not significantly differ between the groups. Overall, the in-hospital mortality rate was 39.8%, and the median hospital length of stay was 21.0 days (0.0-53.5 days). The in-hospital mortality was significantly lower in the TAE group than in the non-TAE group (23.1% vs 44.6%; odds ratio [OR], 0.37; 95% confidence interval [CI], 0.14-1.02; p = 0.048). However, patients in the TAE group had a longer median hospital length of stay (39.5 [7.3-53.5] vs 14.0 [0.0-55.3] days, p = 0.072). In the logistic regression model, the use of TAE was extracted as the independent predictor for better outcomes after adjusting for potential confounders (OR, 0.32; 95% CI, 0.66-0.88; P = 0.032). Hypotension, a high Injury Severity Score, aged 60 years or older, and a low Glasgow Coma Scale score were also independently associated with mortality, with an OR of 5.48, 3.99, 3.30, and 2.89, respectively. Conclusions Cases of MFH are rare, but they are associated with a high mortality. Transcatheter arterial embolization use appears to lead to successful outcomes in such cases. Further studies are required to confirm the efficacy of TAE and evaluate its indications and complications.

KW - Japan Trauma Data Bank

KW - life-threatening hemorrhage

KW - maxillofacial fracture

KW - transcatheter arterial embolization

UR - http://www.scopus.com/inward/record.url?scp=85047542473&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047542473&partnerID=8YFLogxK

U2 - 10.1097/SAP.0000000000001405

DO - 10.1097/SAP.0000000000001405

M3 - Article

C2 - 29664830

AN - SCOPUS:85047542473

VL - 80

SP - 664

EP - 668

JO - Annals of Plastic Surgery

JF - Annals of Plastic Surgery

SN - 0148-7043

IS - 6

ER -